SEC Form 4 · accession 0000899243-16-017456
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric D. Shaff
Officer — CFO and EVP
Period of report
Mar 31, 2016
Accepted (ET)
Apr 4, 2016 · 7:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 31, 2016 | M | 7,663 | $7.79 | A | 7,663 | D | |
| Common Stock | Mar 31, 2016 | S | 1,095 | $25.13 | D | 6,568 | D | |
| Common Stock | Mar 31, 2016 | S | 6,568 | $26.50 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $7.79 | Mar 31, 2016 | M | 7,663 | D | — | Dec 8, 2024 | Common Stock | 7,663 | 249,556 | D |
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- F2The option vested as to 25% of the shares subject to the option on November 17, 2015, and has vested or will vest as to an additional 6.25% of the total number of shares subject to the option upon the completion of each three consecutive months of service thereafter.